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Abstract
Background: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances
and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative
disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no
approved drugs for mitigating the acute or chronic effects of TBI.
Methods: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were
evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI intravenous
administration of Pom (0.5 mg/kg at 5 or 7 h and 0.1 mg/kg at 5 h) was evaluated on functional and histological
measures that included motor function, fine more coordination, somatosensory function, lesion volume, cortical
neurodegeneration, neuronal apoptosis, and the induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).
Results: Pom 0.5 mg/kg administration at 5 h, but not at 7 h post-TBI, significantly mitigated the TBI-induced
injury volume and functional impairments, neurodegeneration, neuronal apoptosis, and cytokine mRNA and
protein induction. To evaluate underlying mechanisms, the actions of Pom on neuronal survival, microglial
activation, and the induction of TNF-α were assessed in mixed cortical cultures following a glutamate
challenge. Pom dose-dependently ameliorated glutamate-mediated cytotoxic effects on cell viability and
reduced microglial cell activation, significantly attenuating the induction of TNF-α.
Conclusions: Post-injury treatment with a single Pom dose within 5 h significantly reduced functional impairments in
a well-characterized animal model of TBI. Pom decreased the injury lesion volume, augmented neuronal survival, and
provided anti-inflammatory properties. These findings strongly support the further evaluation and optimization of Pom
for potential use in clinical TBI.
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Background
Traumatic brain injury (TBI) is the leading cause of
death and long-term disability in the developed world.
Annually, an estimated ten million people suffer a TBI
event worldwide [1, 2]. Projections indicate that TBI will
comprise the third largest portion of the total global dis-
ease burden by 2020 [1]. Within the USA, an estimated
1.7 million people per year sustain a TBI, and approxi-
mately 5.3 million people live with a TBI-induced dis-
ability [3, 4]. Within Taiwan, an estimated 52,000 TBIs
occur annually, and up to 25 % of them are fatal [5].
With increases in survival following initial injury, TBI
can result in substantial and lifelong cognitive, physical,
and behavioral impairments that require long-term ac-
cess to health care and disability services [6, 7]. Specific-
ally, some 70–90 % of patients continue to manifest
prolonged and often permanent neurocognitive dysfunc-
tions that can substantially impact their performance
and/or quality of life. Additionally, epidemiological evi-
dence points to an elevated prevalence of military vet-
eran survivors of TBI developing dementia in later life
[8], with an increased risk of Alzheimer’s disease, Parkin-
son’s disease, and amyotrophic lateral sclerosis [9]. In
light of the lack of any available therapeutic [10], it is
important to understand the mechanisms underpinning
TBI in order to develop effective strategies that can at-
tenuate the neuronal dysfunction and loss that ensues
from head injury.
TBI-associated brain damage can be segregated into
two key phases. First, an initial primary damage phase
occurs at the moment of insult and includes contusion
and laceration, diffuse axonal injury, and intracranial
hemorrhage that results in immediate (necrotic) cell
death [11, 12]. This is followed by an extended second
phase that encompasses cascades of biological processes
initiated at the time of injury that may persist over sub-
sequent days, weeks, and, possibly, months, consequent
to ischemia, neuroinflammation, glutamate toxicity, al-
tered blood-brain barrier permeability, oxidative stress,
astrocyte reactivity, cellular dysfunction, and apoptosis
[13–16]. As secondary brain injury may be reversible, to
develop an effective treatment, it is imperative to under-
stand the biological cascades that drive the delayed sec-
ondary phase subsequent to TBI [10, 11].
TNF-α, a key pro-inflammatory cytokine, is synthe-
sized and released by activated microglial cells. Once
released and if not appropriately time-dependently re-
stored to a non-activated state, microglial dysregulated
TNF-α generation can initiate a self-propagating cycle of
unchecked inflammation that can drive neuronal dys-
function and disease processes [17]. Pharmacological
interruption of this cycle may be of significant benefit
for disorders with a neuroinflammatory component.
The drug “thalidomide” can lower TNF-α protein
levels post-transcriptionally by accelerating degradation of
TNF-α messenger RNA (mRNA) [18]. However, it is not a
particularly potent TNF-α synthesis inhibitor in vivo and
is associated with sedation, serious teratogenic adverse ef-
fects, and neurotoxicity at high clinical doses [19]. In the
light of our recent studies demonstrating that the novel
and more potent TNF-α synthesis inhibitor 3,6′-dithiotha-
lidomide could effectively mitigate the neuronal apoptosis,
gliosis, and behavioral impairments instigated by weight
drop-induced mild TBI in mice [20] and other neurode-
generative conditions [21, 22], in the present study, we
evaluated a clinically available, more potent amino thal-
idomide analog, pomalidomide (Pom), in a moderate to
severe TBI model. Pom is an immunomodulatory agent
with a reported TNF-α inhibitory action of up to 50,000-
fold greater than thalidomide [23], whose additional
suppressive effects on angiogenesis and tumor cell prolif-
eration underpin its use and efficacy in the treatment of
multiple myeloma and other cancers [24].
In the present study, we assessed the effects of the US
Food and Drug Administration (FDA)-approved drug
Pom on mediators of secondary injury in a rodent model
of a penetrating brain injury, resulting from controlled
cortical impact. A single Pom treatment provided favor-
able outcomes across a broad series of acute histological
and functional measures at a clinically relevant dose
[25]. This study strongly supports further investigation
of Pom in additional models of TBI to evaluate potential
translational applications in human TBI.
Methods
In vivo studies
Animal model of TBI and drug administration
All animals were treated in accordance with the Inter-
national Guidelines for animal research. The study de-
sign was approved by the Animal Ethics Committee of
Taipei Medical University. All procedures undertaken
were covered under the following animal study protocol:
LAC-2015-0051. Animals were housed in a temperature
(21–25 °C)- and humidity (45–50 %)-controlled room
with a 12-h light/dark cycle with ad libitum access to
pellet chow and water. Male Sprague–Dawley rats
(250–300 g, body weight) were anesthetized with 8 %
chloral hydrate (400 mg/kg; Sigma, St. Louis, MO)
and placed in a stereotaxic frame. A 5-mm craniotomy
was performed over the left parietal cortex, centered on
the coronal suture, and 3.5 mm lateral to the sagittal su-
ture. TBI was induced using a controlled cortical impact
instrument with a rounded metal tip (5-mm diameter).
The tip was propelled at a velocity of 4 m/s, and it created
a deformation 2 mm below the dura, as described previ-
ously [26–28]. Sham animals received anesthesia and cra-
niotomy but no TBI. To control for fluctuations in rodent
body temperature due to anesthesia or TBI or to drug
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interactions, animal body temperature was monitored by
the use of a rectal probe and was maintained at 37.0 ±
0.5 °C using a heated pad. Thereafter, animals were placed
in a heated cage to maintain body temperature while re-
covering from anesthesia. To further assess for potential
changes in body temperature induced by Pom and
anesthesia, a series of sham and TBI animals were ad-
ministered with both doses of drug and their body
temperature was likewise monitored over a 3-h interval.
All animals were randomly assigned into three main
groups: sham injury (i.e., control animals with craniot-
omy but without the TBI procedure (n = 5)), TBI plus
drug vehicle (veh) (i.e., animals challenged with TBI and
treated with vehicle not containing Pom (n = 5)), and
Pom-treated TBI animals (i.e., animals subjected to TBI
and then treated with Pom). As illustrated in Fig. 1a,
these TBI + Pom treatment animals were then subdi-
vided into several groups based on dose and treatment
time: Pom 0.5 mg/kg administered intravenously at 5 or
7 h (n = 5 for both groups) or Pom 0.1 mg/kg adminis-
tered intravenously at 5 h (n = 5). These animal group
numbers were selected based upon our prior studies
where an n = 5 was sufficient to show statistically signifi-
cant differences in relation to different treatment effects
[28]. Figure 1b depicts the time points for morphological
evaluation of contusion (or lesion) volume, neurodegen-
eration, and apoptosis or biochemical measurement of
cytokine mRNA and protein levels. Our selected treat-
ment times of 5 and 7 h were based on our prior studies
indicating that the secondary phase of neuronal apop-
tosis following CCI TBI can be inhibited if appropriate
treatment is initiated within this time window [28].
Finally, our selected doses of Pom were based on
dose translation from rat to human studies, based on
normalization of body surface area between species in
accord with FDA guidelines.
Pom synthesis and vehicle
Pom, 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-
dione, was synthesized from 3-nitrophthalic anhydride
and 2,6-dioxopiperidine-3-ylamine trifluoroacetate by re-
flux in acetic acid under a nitrogen atmosphere to afford
2-(2, 6-dioxopiperidine-3-yl)-4-nitrophthalimide. This
product was characterized, purified, and then reacted with
palladium on activated carbon in methanol under an at-
mosphere of hydrogen to generate Pom. Filtration and
purification by chromatography followed by chemical
characterization verified the structure of the final product
as Pom with a purity of >99.5 %. The drug vehicle com-
prised of a mixture of dimethyl sulfoxide (DMSO, Sigma,
St. Louis, MO) in normal saline (10 % DMSO in saline)
that was administered by i.v. injection.
TBI and TBI plus Pom effects on injury volume
To measure the volume of TBI-induced injury in the left
parietal cortex 24 h after TBI, cresyl violet-stained sec-
tions were digitized and analyzed using a ×1 objective
and evaluated using ImageJ (National Institutes of
Fig. 1 Scheme of animal study design. a For contusion volume (or lesion) and behavioral analyses, animals were submitted to TBI or a sham
procedure at time zero; thereafter, they were dosed with either vehicle (veh) or pomalidomide (Pom) at either 5 or 7 h later. Behavioral analyses
were performed after 24 h, and thereafter, animals were euthanized for evaluation of contusion volume. b For morphological evaluation of
neurodegeneration and apoptosis or biochemical measurement of cytokine mRNA and protein levels, animals were subjected to TBI or a sham
procedure at time zero; thereafter, they were dosed with either vehicle (veh) or pomalidomide (Pom) at 5 h and were euthanized at either 8 or
24 h. For each group, n = 5
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Health, Bethesda, MD). The injury volume measurement
was performed as previously described [26]. The injury
area was calculated from all images of cresyl violet-
stained sections from the brain region of interest. The
volume was computed by adding the areas and was
multiplied by the inter-slice distance (in this situation
500 μm). Hemisphere tissue loss was expressed as a per-
centage that was calculated by the use of the following
formulae: [(contralateral hemispheric volume − ipsilateral
hemispheric volume) / (contralateral hemispheric vol-
ume) × 100 %], as previously reported [29]. The percent-
age of tissue loss was determined for each animal, and a
mean value was then generated and used to create a plot
of injury volume per treatment group; the percentage of
tissue loss was used for statistical analysis.
TBI and TBI plus Pom effects on numbers of degenerating
cortical neurons
Schmued and Hopkins initially described an immunohis-
tochemical method that was able to identify degenerat-
ing neurons by the use of an anionic fluorescein
derivative stain called Fluoro Jade B [30]. In the present
study, we used a similar yet more sensitive agent, Fluoro
Jade C (FJC) to identify TBI-induced degenerating neu-
rons [31]. Specifically, we used a Fluoro-Jade C from a
ready-to-dilute staining kit (Biosensis, TR-100-FJ), with
some modification [28]. Brain sections from the different
treatment groups were de-paraffinized, followed by a re-
hydration step in distilled water for 2 min. The slides
were incubated in a 1 in 15 diluted solution of potas-
sium permanganate for 10 min, rinsed in distilled water
for 2 min and incubated in a 1:25 diluted FJC solution
for 30 min. The slides were then washed and mounted
on coverslips with Vecta-shield mounting medium (Vector
Laboratories, Burlingame, CA, USA). All sections were ob-
served and photographed with a fluorescence microscope;
slides were exposed to an excitation light source of
450–490 nm with the resulting emission at 521 nm
recorded and analyzed. The numbers of FJC-positive
cells were counted in five randomly selected fields
per slide by means of SPOT image analysis software
(Diagnostic Instruments, Sterling Heights, MI). The
numbers of FJC-positive cells observed on the slides
from the different treatment groups were counted
and used to generate a mean number per treatment
group. The mean numbers of FJC-positive cells were
then plotted and used for statistical analysis.
Assessment of motor function and neurological outcome
following TBI and Pom-treated TBI
All analyses were performed in a non-biased, blinded
manner. Where a baseline measurement or specific pre-
injury training was required for motor function analysis,
observations/trainings were undertaken prior to and
24 h after TBI. Assessments included an (i) elevated
body swing test, (ii) a beam walk test, (iii) a tactile adhe-
sive removal test, and (iv) a neurological severity score
(NSS). As TBI was performed on the left side of the
brain, any resulting motor functional impairments devel-
oped on the right side.
Asymmetrical motor function
Body asymmetry was quantitatively analyzed by the use
of the elevated body swing test (EBST), as initially de-
scribed by Borlongan and co-workers [32]. Briefly, ani-
mals were examined for lateral movement/turning when
their bodies were suspended 10 cm above the testing
table. The animals were lifted from the table while held
by the base of the tail. A left/right swing was counted
when the head/torso of the animal moved more than a
10° angle from its vertical axis after elevation. The fre-
quency of the left/right swings was scored across 20
consecutive trials and expressed as a percentage calcu-
lated as follows: [(number of right-biased swings/ the
total number of swings) × 100 %]. An uninjured animal
shows an equal frequency to swing to either the left or
right side. The number of contralateral rotations was de-
termined and used to generate a mean number of rota-
tions for each treatment group, which then was
statistically analyzed.
Fine motor coordination
TBI-induced disturbance in fine motor coordination was
assessed by the use of the beam walk test [33]. Each ani-
mal was placed onto a brightly illuminated platform.
Due to a rodent’s inherent preference for a darkened
enclosed environment, as compared to an open illumi-
nated environment, each animal was allowed to move
freely towards and to enter a darkened goal box [27].
The beam was constructed with the following dimen-
sions: 2.5 cm × 122.0 cm. The time taken for each animal
to traverse the beam to reach the goal box was recorded
(with the caveat that total time was not to exceed 60 s).
Five trials were recorded for each animal before TBI and
then at 24 h after TBI. The mean times to traverse the
beam were calculated, and a plot was generated to evalu-
ate treatment effects on beam walk times; these times
were used for statistical analysis.
Somatosensory function assessment
A tactile removal test was used to evaluate somatosen-
sory function; this test measures the ability of the animal
to perform sensitive paw to mouth movements and
mouth, paw dexterity. Essentially, two small adhesive
stickers were used as bilateral tactile stimuli that were
placed on the distal–radial region on the wrist of each
forelimb [27, 34]. Animals were pre-trained daily for
3 days before TBI, and the time required (no longer than
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3 min) for the animal to remove the sticker from the
forelimb was recorded for five trials undertaken 24 h
after TBI. The mean time taken to remove the stickers
from the last trial was used to generate a plot displaying
the latency time of the sticker removal from each paw;
the times were used for statistical analysis.
Neurological severity score
To compare any neurological deficit severities in TBI an-
imals, a modified neurological severity score (mNSS)
was performed. The mNSS included a composite of
motor, sensory, reflex, and balance tests [27]. One point
was scored for the inability to perform the test or for the
lack of a tested reflex. Accordingly, the higher the mNSS
score the more severe the injury; neurological function
was graded on a scale of 0–18 (a normal animal score
being 0 and a maximally impaired animal score being
18). The overall score generated for each animal was de-
termined, and then, a mean for each treatment group
was calculated and used to create a plot displaying the
average mNSS for each treatment group. The scores
were used then for statistical analysis.
TBI and TBI plus Pom effects on numbers of apoptotic
cortical neurons
Immunohistochemical analyses of the level of TBI-
induced apoptosis were performed as has been previously
described [28]. To assess for early detection of apoptosis,
a series of animals were euthanized at 8 h (n = 5) in
addition to 24 h (n = 5) post-TBI (Fig. 1b). Cellular
changes observed to occur during apoptosis include the
externalization of the phospholipid phosphatidylserine
(PS). Specifically, the translocation of PS, from the inner
membrane to the outer membrane, is used routinely as a
marker in the early stages of apoptosis. Annexin V binds
strongly with PS, and its detection has been widely used
for imaging of apoptosis both in vitro and in vivo; thus, to
label external PS, we stained for the protein annexin V
[35, 36]. In brief, all sections were dried and then rehy-
drated in phosphate-buffered saline (PBS). The sections
were blocked for 1 h in a 5 % bovine serum albumin
(BSA, Sigma, St. Louis, MO) PBS-based buffer after which
they were incubated with the appropriate primary anti-
bodies. To detect mature neurons, a monoclonal anti-
NeuN antibody (Millipore; 1:500) was used. To detect
annexin V, an anti-annexin V antibody was used (Abcam;
1:500). All primary antibody incubations took place at 4 °C,
overnight. Primary antibody detection was undertaken with
fluorescent secondary antibodies: Alexa Fluor® 488 goat
anti-rabbit IgG (1:200, Jackson ImmunoResearch, West
Grove, PA) and Alexa Fluor® 594 anti-mouse IgG (1:200
dilution, Jackson ImmunoResearch, West Grove, PA).
Tissue samples were incubated with secondary anti-
bodies at room temperature for 2 h and were then
treated with Mounting Medium H-1000 (Vector
Laboratories, Burlingame, CA, USA). The numbers of
dual stained NeuN- and annexin V-positive cells were
then counted in five randomly selected fields per slide
in five slides, by means of SPOT image analysis soft-
ware (Diagnostic Instruments, Sterling Heights, MI).
Numbers of NeuN- and annexin V-positive neurons
observed on the slides from the different treatment
groups were used to calculate a mean number of
apoptotic neurons per animal. This value was then
used to generate a mean number per treatment
group. The mean numbers of double-positive neurons
were plotted and statistically analyzed.
TBI and TBI plus Pom effects on mRNA levels of
pro-inflammatory cytokines
Total RNA was prepared from cortical tissue (approxi-
mately 50 mg) 8 h post-injury (n = 5) by the use of TRI-
zol reagent (Invitrogen, Life technologies, Carlsbad, CA,
USA); the protocol used was as recommended by the
manufacturer. The quality and concentration of the total
RNA were determined by measuring absorbance at 260
and 280 nm wavelengths. Total RNA (3 μg) underwent
reverse transcription (RT) that was followed by a com-
plementary DNA (cDNA) synthesis step. The RT step
was performed using a total reaction volume of 20 μl
with ReverTra Ace® set number PU-TRT-100 (Purigo,
Taipei, Taiwan). The RT products were used as templates
in quantitative (real-time) PCR or were stored at −20 °C.
The quantification of target mRNA levels was performed
using the qPCR QuantiFast SYBR Green PCR kit (Qiagen)
with primers in a Rotor-Gene Q 2plex HRM Platform
(Qiagen). Reaction conditions were carried out for 35–
40 cycles (5 min at 95 °C, 10 s at 95 °C, and 30 s at 60 °C).
The primers were designed using reported cDNA se-
quences: TNF-α, CTC TTC TCA TTC CCG CTC GTG
(forward) and GGA ACT TCT CCT CCT TGT TGG G
(reverse); IL-1β, GTT TGA GTC TGC ACA GTT CCC
(forward) and CAA CTA TGT CCC GAC CAT TGC (re-
verse); IL-6, TTC TTG GGA CTG ATG TTG TTG AC
(forward) and AAT TAA GCC TCC GAC TTG TGA AG
(reverse); and β-actin, GAC CCA GAT CAT GTT TGA
GAC CTT C (forward) and GAG TCC ATC ACA ATG
CCW GTG G (reverse). Relative transcript expressions of
inflammatory target mRNAs were normalized to β-actin,
which was used as an internal control. Transcript levels
were expressed as values relative to the control group
using the comparative cycle threshold (Ct) method.
Effects of Pom on the TBI or excitotoxicity activation of
pro-inflammatory cytokine proteins
Rat cortical tissues were harvested 8 h post-injury
(n = 5), homogenized in lysis buffer (RIPA, Sigma, St
Louis, MO), and centrifuged at 8000g for 10 min at
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4 °C. The resulting supernatant was collected and
stored at −80 °C until the time of analysis of protein
levels by specific ELISAs for rat TNF-α, IL-1β, and
IL-6 (R&D System (RTA00; RLB00; R6000B)). The
sample protein content was determined by the use
of the BCA assay (Pierce™ BCA Protein Assay Kit,
#23225), and levels of cortical protein were determined
by following the manufacturers protocol. Cortical cytokine
protein levels were normalized to a pg/mg of tissue unit.
In vitro studies
Pom effects on excitotoxic and oxidative stressors of rat
primary cortical cultures
Primary cortical neuronal/glial co-cultures were isolated
from the cerebral cortex of 1-day-old neonatal Sprague–
Dawley rats, as previously described [37]. These proce-
dures were performed in accordance with the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals and were approved by the Institu-
tional Animal Care and Use Committee of Taipei Med-
ical University, Taipei, Taiwan (animal study protocol
number LAC-2015-0051). Rat pup brains were removed
immediately following euthanasia and the cerebral
cortex placed in ice-cold Hank’s solution (without
Ca2+ or Mg2+). Cortical cells were dissociated and
suspended in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco BRL, Grand Island, NY, USA) sup-
plemented with 10 % fetal bovine serum (FBS).
Thereafter, cells were plated at a density of 5 × 105
cells/ml in 24-well culture plates and then incubated
at 37 °C in a humidified incubator (5 % CO2, 95 %
air). All experiments were performed 13–14 days
after the plating (100 % confluency), with N = 3 for
each treatment and control group.
The percentage of neurons, astrocytes, and microglial
cells were assessed by immunostaining. Mature neurons
were stained with NeuN (Millipore; 1:500), astrocytes
with anti-GFAP (Millipore ab5804; 1:1000), and acti-
vated microglia with anti-CD68 antibody (clone ED1,
ab31630, abcam 1:500). Under our culture conditions,
the neuronal/glial co-cultures comprised of approxi-
mately 35 % of neurons, 54 % astrocytes, and fewer
numbers of microglia (6 to 8 %), in line with our previ-
ous studies [28, 37]. To mimic TBI-induced excitotoxi-
city stress in vitro, neuronal/glial co-cultures were
challenged with glutamate (Sigma, St Louis, MO). Differ-
ent concentrations of stressor were used to assess the
levels of excitotoxicity (not shown). From these pilot
studies, 24 h challenge with 100 mM glutamate was ob-
served to be sufficient to cause a non-maximal level of
neuronal cellular loss, and hence, this time and concen-
tration were selected for all following experiments. To
evaluate potential neuroprotection afforded by Pom
against the stressor toxicity, different concentrations of
Pom (3 to 100 μM) or vehicle (0.1 % DMSO in PBS)
were added 30 min after initiation of a 24-h challenge
with glutamate (100 mM).
The effects of Pom treatment on cortical culture
media levels of glutamate-induced microglial TNF-α
protein generation were determined over time. Pom
(100 μM) was administered 30 min after challenge with
the stressor, and culture media was harvested for ana-
lysis at 3, 6, and 24 h after the stressor challenge. Protein
levels of rat TNF-α were measured in culture media by
ELISA (R&D System RTA00) according to the manufac-
turer’s protocol, and the results are expressed as pg/ml.
Statistical analysis
Comparisons between treatment groups were conducted
using one-way ANOVA with a post hoc test. The Bonfer-
roni correction was used for repeated measures. All statis-
tical analyses and bar graph displays were carried out
using Sigma Plot and Stat version 2.0 from Jandel Scien-
tific, San Diego, CA. Data are presented as mean ± stand-
ard error of the mean (S.E.M.) values, and statistical
significance (*p < 0.05, **p < 0.01 or ***p < 0.001) is
noted in the legend of each figure.
Results
TBI injury in rodent
Pom treatment dose- and time-dependently reduced TBI
injury volume
TBI caused cortical tissue injury that resulted in a loss of
volume in the ipsilateral hemisphere (Fig. 2a). The injury
volume observed in the TBI + veh animals was in the
order of 21 ± 3 % of the contralateral hemisphere vol-
ume. Post-injury administration of Pom (0.5 mg/kg, i.v.)
at 5 h significantly reduced the injury volume to 10
± 1 % of the contralateral hemisphere volume. This
represented a reduction of the lesion volume in the
order of 54 ± 2 % compared to the TBI + veh group
(p < 0.01). Pom (0.1 mg/kg, i.v.) at 5 h reduced the
injury volume to ~14 ± 1 %, representing a 34 ± 2 %
reduction that was not significantly different from
the TBI + veh group (Fig. 2b).
To evaluate the importance of time dependence of
drug administration after TBI to define a window of op-
portunity, a comparison of the most effective dose of
Pom (0.5 mg/kg, i.v.) was made when administered at
5 h compared to 7 h post-TBI. As previously noted, ad-
ministration of Pom at 5 h significantly reduced the con-
tusion volume. However, delaying administration to 7 h
post-TBI resulted in no significant reduction in injury
volume with a difference of 1.0 ± 1.0 % compared to the
TBI + veh group (Fig. 2c). As Pom proved to be effica-
cious at reducing the injury volume at 5 h but not at 7 h
post-TBI, we chose to study Pom (0.5 mg/kg, i.v.) at 5 h
post-TBI for all subsequent experiments.
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Pom treatment reduced TBI-induced neurodegeneration
As illustrated in Fig. 3a, numerous FJC-positive cells
were observed within the cortical contusion margin at
24 h post-injury. A quantitative summary of FJC-positive
cells observed in the different treatment groups is pro-
vided in Fig. 3b. There were significant levels of degener-
ating neurons in the TBI + veh group, as compared to
sham animals (468 ± 26/mm2, four slides per animal
from n = 5 animals). In comparison, the Pom-treated
TBI group (Pom 0.5 mg/kg, 5 h) had a significantly
lower number of degenerating neurons (268 ± 37/mm2,
four slides per animal from n = 5 animals) compared to
the TBI + veh group. This difference represents a signifi-
cant reduction of ~43 % compared to the vehicle treat-
ment group (p < 0.01).
Pom improved multiple functional outcomes as revealed
by behavioral evaluation at 24 h after TBI
As evident in Fig. 4, TBI induced numerous changes in
rodent motor function that were attenuated by treat-
ment with Pom. Notably, no changes in body
temperature regulation were observed in any sham or
TBI animals, whether administered Pom (0.1 or 0.5 mg/kg)
or veh at 5 or 7 h following TBI.
Asymmetrical motor function, as evaluated by ele-
vated body swing that combines assessments of tact-
ile/sensory and motor functions [32], was identical
prior to TBI across all animals, yet after TBI, signifi-
cant differences were apparent by 24 h after injury.
Specifically, asymmetry was elevated in TBI + veh ani-
mals, as compared to sham levels (Fig. 4a), with an
increase in the contralateral swing ratio in TBI + veh
animals. Pom (0.5 mg/kg) treatment at 5 h post-TBI
significantly improved functional deficits by reducing
the contralateral swing ratio from 91 ± 3 to 74 ± 8 %
(p < 0.05), a decline of 17 %.
Fine motor coordination, as evaluated by the beam
walk test as a task that combines assessments of motori-
city/coordination and anxiety, similarly was identical
across groups prior to TBI, yet after TBI, significant im-
pairments were observed at 24 h post-injury (Fig. 4b).
Beam walk latency time was elevated following TBI and
was significantly different between sham-, TBI + veh-,
and Pom (0.5 mg/kg)-treated TBI animals. The Pom
group treated at 5 h post-injury demonstrated
Fig. 2 Post-injury administration of pomalidomide (Pom: 0.5 mg/kg, i.v.) at 5 h after TBI significantly reduced contusion volume evaluated at 24 h.
A lower Pom dose (0.1 mg/kg i.v.) and longer time window (7 h) reduced efficacy. a Representative cresyl violet stained coronal brain sections of
the CCI TBI-induced cavity in Sham (control without TBI), TBI-vehicle (TBI + veh), and pomalidomide-treated TBI rats (TBI + Pom) at 24 h post-TBI.
b The TBI-induced contusion volume evaluated at 24 h was significantly reduced by Pom (0.5 mg/kg), but not by Pom (0.1 mg/kg) treatment.
c Post-injury administration of Pom (0.5 mg/kg) at 5 h, but not at 7 h, significantly reduced the contusion volume relative to TBI + vehicle
(TBI + veh) group. Data are expressed as mean ± S.E.M. (n = 5 in each group). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the sham group.
##p < 0.01 compared with the TBI + veh group
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significantly better performance in beam walking with a
latency of 32 ± 8 s (p < 0.001) compared to 59 ± 2 s for
the TBI + veh animal group.
Modified neurological severity score assessment pro-
vided a composite evaluation of a broad series of sensory
and motor functions [38] and demonstrated that TBI in
the left cortical hemisphere resulted in physiologically
relevant functional deficits (Fig. 4c). As compared with
the sham, the TBI + veh group had a significantly in-
creased mNSS score (9.6 ± 0.7 units). Post-injury admin-
istration of Pom 0.5 mg/kg, but not 0.1 mg/kg, at 5 h
mitigated neurological deficits, as revealed by a signifi-
cantly lower mNSS score (p < 0.001) that was 55 ± 4 % of
the TBI + veh group.
Somatosensory function, as evaluated by the time taken
for adhesive sticker-removal from the contralateral paw of
rodents subjected to TBI as a task that combines sensory
and motor skills, was impaired following TBI (Fig. 4d). Sham
animals removed the sticker from both contralateral and ipi-
silateral paws with equal dexterity and speed. However, the
TBI + veh and TBI + Pom groups showed functional deficits,
requiring a significantly greater time for removal of stickers
from their contralateral paw, compared to the sham group.
For the TBI + veh group, the removal time was 163 ± 8 s, as
compared to 5 ± 1 s (sham) (p < 0.001). TBI + Pom 0.1 and
0.5 mg/kg animal groups took longer (157 ± 14 and 99 ±
24 s, respectively) to remove the contralateral sticker com-
pared to the sham group (5 ± 1 s, p < 0.001). However, the
TBI + Pom (0.5 mg/kg) animals were less impaired than the
TBI + veh group, requiring a significantly shorter time to re-
move the contralateral sticker (99 ± 24 s compared to 163 ±
8 s; p < 0.05 versus TBI + veh group).
Pom reduced the numbers of apoptotic neurons induced
by TBI
Significant levels of apoptosis occur in the injured
cortex after TBI. Initially, we assessed for levels of
apoptotic cells at 8 h after TBI. Shown in Fig. 5a are
representative cortical sections illustrating numbers of
neuronal cells (NeuN, labeled red) and apoptotic-
labeled cells (annexin V labeled green). In TBI + veh
animals, the numbers of dual stained apoptotic cells
(shown in the “merged” image Fig. 5a) were signifi-
cantly increased at 8 h after injury, as compared with
sham animal tissues. Specifically, the number of apop-
totic neurons was 137 ± 14 cells/mm2, (p < 0.001 versus
sham) (Fig. 5b). Pom administration reduced the number
of dual stained apoptotic neurons to 76 ± 12 cells/mm2,
thus decreasing the level of neuronal apoptosis by 45 %, as
compared with the TBI + veh group (p < 0.01; Fig. 5b).
Fig. 3 TBI induces neuron degeneration within the contusion region, and treatment with Pom significantly reduced the number of TBI-induced
degenerating neurons. a Representative cresyl violet stained coronal brain section of the Sham (control without TBI) that shows the area of evaluation.
b Representative photomicrographs showing the presence of FJC-staining at 24 h in the sham (control without TBI), TBI + veh group, and TBI + Pom
administered 5 h post-injury group. c Quantitative comparison of mean densities of FJC-positive cells in the cortical contusion area at 24 h post-injury. There
was a significant decrease in the number of FJC-positive cells in the TBI + Pom group. Mean ± S.E.M. (n= 5 in each group). **p< 0.01, ***p< 0.001 compared
with the sham group. ##p<0.01 compared with the TBI + veh group. Scale bar= 100 μm
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Upon examination of the numbers of TBI-induced
apoptotic neurons determined at 24 h after injury
(Fig. 5c), we similarly observed a significant number
of apoptotic neurons in TBI + veh brain (189 ± 28
cells/mm2, p < 0.001 versus sham Fig 5d). Treatment
with Pom markedly reduced dual stained apoptotic
neuron number to 55 ± 2 cells/mm2; thereby decreas-
ing the level of neuronal apoptosis by 71 %, as com-
pared with the TBI + veh group (p < 0.001; Fig. 5 c, d).
Pom reduces TBI-induced cortical cytokine mRNA
expression and protein abundance
Levels of mRNA for the cytokines in sham animals were de-
termined to be low, in accord with the unchallenged status
of the brain. However, on evaluation 8 h after TBI, the ex-
pression of TNF-α mRNA was significantly elevated com-
pared to sham animals; the fold change was +39 ± 4, p <
0.001, Fig. 6a. The levels of expression of IL-1β and IL-6
were also significantly elevated compared to sham levels
(+63 ± 8-fold and +1275 ± 261-fold, respectively, p < 0.001,
Fig. 6 b, c). Pom significantly decreased the expression of all
pro-inflammatory cytokine mRNA levels. The percentage
reduction from the TBI-veh levels for each cytokine was
determined to be, for TNF-α (78 %, p < 0.001), for IL-1β
(50 %, p < 0.05), and for IL-6 (52 %, p < 0.01).
We also compared the cortical protein abundances of
TNF-α, IL-1β, and IL-6 in sham, vehicle-treated and Pom-
treated TBI groups (Fig. 6 d–f). Basal protein levels were
low in the cortical tissue of the sham group. Eight hours
following TBI, cytokine protein levels in cortex were signifi-
cantly elevated in the vehicle-treated group (p < 0.001):
TNF-α 146 ± 15 pg/mg of total protein, IL-1β 356 ± 12 pg/
mg, and IL-6 531 ± 46 pg/mg. Pom significantly reduced
the TBI-induced increase in cortical levels of all three pro-
inflammatory cytokines. Specifically, these protein levels
in Pom-treated TBI rats were lowered by 45 % for TNF-α
(p < 0.001), 31 % for IL-1β (p < 0.001), and 30 % for IL-6
(p < 0.001), as compared to TBI-veh tissue samples.
Primary cortical mixed cell cultures studies: Pom protects
neurons and attenuates the activation of microglial cells
from glutamate-induced excitotoxic 24 h stress
Immunocytochemical studies showed that 24 h following a
challenge with glutamate (100 mM), the proportion of
Fig. 4 Pom administered at 5 h post-injury improved functional outcomes as revealed by behavioral evaluation at 24 h after TBI. a Motor asymmetry
measured by elevated body swing test (EBST). TBI-induced deficits were attenuated by Pom (0.5 mg/kg). b Motor coordination and balance measured
by beam walking test. TBI impairments were attenuated by Pom (0.5 mg/kg). c Animals treated with Pom (0.5 mg/kg), overall presented with better
neurological severity scores (mNSS), as indicated in the animal groups scores shown in (c). d TBI induced abnormalities in sensory/motor function that
were revealed by a longer latency for the animals to remove an adhesive sticker from their contralateral (c) but not ipsilateral (I) forepaw. Treatment
with Pom (0.5 mg/kg) significantly attenuated this behavioral deficit. Data represent the mean ± S.E.M. (n = 5 in each group). *p < 0.05, ***p < 0.001
versus sham group; #p < 0.05, ###p < 0.001 versus TBI + Veh group; +++p < 0.001 versus non-impaired left
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neurons (NeuN+ cells) in a cortical mixed cell culture de-
clined from 36 ± 3 % control cultures to 14 ± 1 % in
glutamate-alone challenged cultures (p < 0.001) (represent-
ing a 61 % loss of the total neuron number). However, when
Pom was added to the cultures 30 min after glutamate, there
was a concentration-dependent attenuation of glutamate-
induced neuron loss (Pom 3, 10, 30, 50, and 100 μM; Fig. 7
a, c), with the highest dose rescuing 37 % of dying neurons.
Microglial cell activation was elevated by glutamate
(100 mM) challenge, as indicated by elevated numbers of
CD68+ cells (2.25-fold greater than control levels). Pom at-
tenuated the proportion of activated microglia, reaching
statistical significance at a Pom concentration of 100 μM (p
< 0.05 versus the glutamate alone group; Fig. 7 b, d) (redu-
cing glutamate-induced microglial activation by 64 %).
Glutamate-induced microglial generation of TNF-α
protein measured in culture media over time is
mitigated by Pom
Based upon the optimal efficacious concentration of Pom
observed from the glutamate study, a similar 100 μM Pom
concentration was evaluated for actions on TNF-α gener-
ation. As illustrated in Fig. 8, glutamate (100 mM) chal-
lenge of cortical mixed cell cultures resulted in microglial
cell activation and the time-dependent synthesis and re-
lease of elevated TNF-α protein levels into the culture
media. Specifically, TNF-α levels rose from a resting con-
centration of 3 to 110 pg/ml at 24 h after glutamate chal-
lenge. Pom significantly attenuated the effects of
glutamate at all times evaluated during the study, reducing
TNF-α levels in media by 45 % (Fig. 8).
Discussion
TBI is typically subdivided into time-dependent compo-
nents. This consists of an initial primary injury that in
the present study involves a focal, physical deformation
of the dura mater, and a series of secondary events that
include inflammatory, oxidative stress, and excitotoxicity
response-related pathology [39]. In the present study, we
used a well-characterized controlled cortical impact
model of TBI. In this model, the primary injury, depend-
ing on the severity, typically leads to the formation over
Fig. 5 Post-injury administration of Pom at 5 h after TBI decreased annexin V-positive neurons at 8 and 24 h. a Immunofluorescence of annexin V and NeuN
in cortical brain tissue at 8 h post-injury. Annexin V immunoreactivity (a marker of early apoptosis) is shown in green; NeuN (a marker for mature neurons) is
shown in red. Merged red and green cells are shown as yellow, which highlights dual labeled cells suggesting an apoptotic neuronal state. Cells illustrated in
the inset box in the lower right section of the merged images are magnified examples of the cells indicated in the smaller observation box. b Treatment with
Pom significantly reduced the number of dual stained annexin V-positive neurons, indicating a lower incidence of apoptotic neurons. Similar observations are
shown for tissues obtained from animals euthanized at 24 h post-TBI (c, d). TBI induced a significant number of apoptotic neurons at 24 h post-injury, and
treatment with Pom significantly reduced the numbers of apoptotic neurons compared with TBI + veh. Mean± S.E.M. (n=5 in each group). **p< 0.01,
***p< 0.001 compared with the sham group. ##p< 0.01, ###p< 0.001 compared with the TBI + veh group. Scale bar= 100 μm
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time of a necrotic core that is not amenable to pharma-
cological manipulation [39–41]. However, the molecular
effectors responsible for the later, secondary components
of TBI do hold the potential for beneficial drug interven-
tion. Prior studies of others and ourselves utilizing p53
inactivators as pharmacological tools to halt pro-
grammed cell death processes indicate that tissues in the
marginal zone of the focal TBI microenvironment may
be compromised but not yet destined to become irre-
versibly dysfunctional or apoptotic [28, 42]. These are
the tissues predicted most likely to respond to drug
treatment strategies that may enhance cell survival [39].
Key players in secondary damage are cytokine, pro-
inflammatory mediators of inflammation such as TNF-α,
play a significant role in directing cell death pathways,
and, interestingly and somewhat counterintuitively,
also have a role in cell survival pathways [43–45].
TBI-induced activation of brain immune cells can in-
duce upregulations of TNF-α protein that can amplify
additional pathologies associated with secondary
excitotoxicity-related injury such as glutamate release
from astrocytes, which can additionally cause blood-
brain barrier dysfunction and further drive disease
processes [17, 46]. The unchecked generation of TNF-α
may induce a self-propagating pathological cascade of
neuroinflammation and neuronal loss [47] that upregu-
lates multiple cytokines downstream of the TNF-α recep-
tor, such as IL-6, IL-1β, and TNF-α [48]. Evidence of such
elevations are documented in clinical and experimental
TBI CSF and serum from individuals with clinical brain
injuries and in rodent models with experimental brain in-
juries [49–51]. Not surprisingly, numerous animal studies
have adopted anti-inflammatory approaches with drug
benefits having been observed in various models of TBI,
giving added weight to the significance of inflammation in
the secondary pathology of TBI [20, 51–55]. These obser-
vations indicate that inflammation is an interesting target
for study and potentially drug candidate development.
Pom is a third generation derivative of thalidomide
(N-α-phthalimidoglutarimide). Thalidomide, first used in
the clinic in the late 1950s as a non-addictive, non-
barbiturate sedative and then found effective as an anti-
emetic in women suffering from pregnancy-associated
nausea, notably was associated with birth defects and
was rapidly removed from clinical use in the early 1960s
[56–58]. Following the failure of other drugs, the fortuit-
ous use in 1964 of thalidomide as a sedative in a patient
suffering leprosy and the remarkable resolution of the
associated symptoms [59] provided the initial insight of
the compound’s immunomodulatory actions. This
spurred the use and eventual approval of thalidomide as a
treatment of erythema nodosum leprosum, documenting
its now well-characterized anti-inflammatory actions [60],
and the development of structure/activity relations for the
creation of more potent analogs. Moreira and co-workers
determined that thalidomide’s anti-inflammatory properties
Fig. 6 Treatment with Pom 5 h after TBI significantly reduced injury-induced cortical cytokine mRNA expression and protein abundance at 8 h
after TBI. TBI-induced marked elevations in mRNA levels of a TNF-α, b IL-1β, and c IL-6. Treatment with Pom (0.5 mg/kg) significantly attenuated
the elevation in mRNA transcript levels when compared with TBI + veh levels. Changes in cytokine protein abundance mirrored those of mRNA
transcripts (d, e, f). Mean ± S.E.M. (n = 5 in each group). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the sham group. #p < 0.05, ##p < 0.01,
###p < 0.001 compared with the TBI + veh group
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Fig. 7 Pom protected neurons and attenuated the activation of microglial cells from glutamate-induced excitotoxicity 24 h after a challenge with
glutamate. a, b Photomicrographs of the immunochemical staining for NeuN-positive (+) neurons and CD68+ microglial cells are provided.
a Numbers of NeuN+ cells were significantly reduced by treatment with glutamate (100 mM) compared to control (Con) cultures. The addition of
Pom (3–100 μM), 30 min after a challenge with glutamate led to a dose-dependent attenuation in NeuN+ cell loss. Arrows indicate NeuN+ neurons
(brown color) in control, glutamate, and glutamate + Pom (3 or 100 μM) treated cultures. b Staining for CD68+ microglial cells in control cultures,
cultures treated with glutamate (100 mM), cultures treated with glutamate (100 mM), and Pom (3 or 100 μM) are shown. A challenge with glutamate
significantly elevated the numbers of CD68+ cells, treatment with Pom (3–100 μM) significantly attenuated the activation of microglial cells in a
dose-dependent manner. Arrows indicate microglia (brown color). c, d Quantitative summaries of the effects of glutamate and Pom treated cultures on
NeuN+ cells and activated microglial cells are provided. Mean ± S.E.M. (n = 8 in each group). *p < 0.05, **p < 0.01, ***p < 0.001 compared with control
cultures; #p < 0.05 compared with glutamate alone challenged cultures. Scale bar = 50 μm
Fig. 8 Treatment with Pom significantly attenuated a glutamate-induced excitotoxicity-induced elevation of TNF-α protein in primary mixed
cortical culture media. Treatment with Pom (100 μM), 30 min after the addition of glutamate (100 mM for 24 h) significantly reduced the levels of
TNF-α protein detected in culture media. Media samples were obtained at 3, 6, and at 24 h after challenge with glutamate. Mean ± S.E.M. (n = 8
or 6 in each group). ***p < 0.001 compared with control cultures. ##p < 0.01 compared with glutamate alone treated cultures
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are driven by the drug’s ability to reduce the half-life of
TNF-α mRNA, thereby lowering protein levels of this
potent pro-inflammatory cytokine [61, 62]. These initial
studies gave rise to the development of multiple
thalidomide-based immunomodulatory drugs, two of
which (Lenalidomide and Pom) are presently used clinically
for multiple myeloma and other cancers [63].
Our previous side-by-side evaluation of thalidomide,
lenalidomide, and Pom in an established mouse retinal
explant outgrowth assay [64] demonstrated that Pom,
unlike its other analogs, was not associated with neuro-
toxicity at anti-inflammatory concentrations. These
studies, together with our evaluation of thalidomide in a
mouse transgenic model of Alzheimer’s disease in which
it lacked efficacy and failed to lower elevated brain levels
of TNF-α at a clinically translatable dose [65], focused
our attention to more potent anti-inflammatory analogs
[21], including Pom. The findings of our present study
indicate that Pom possesses beneficial properties across a
broad series of outcome measures in a well-characterized
animal model of a penetrating form of TBI. A single ad-
ministration of Pom (0.5 mg/kg, i.v.) at 5 h but not 7 h
after the induction of TBI attenuated the size of the result-
ing cortical lesion, reduced the levels of apoptotic and de-
generating neurons, and, notably, improved multiple
motor functional outcomes evaluated 24 h after injury.
Additionally, measures of TBI-upregulated cortical mRNA
and protein levels of the pro-inflammatory cytokines
TNF-α, IL-1β, and IL-6 were significantly blunted by Pom.
In vitro studies undertaken in mixed cell primary cortical
cultures assessing the effects of Pom on the excitotoxic
stressor glutamate, thought to be important in the cascade
leading to secondary TBI pathology, illustrated both neu-
roprotective and anti-inflammatory (TNF-α lowering) ac-
tivities that may underpin our observed activity of Pom in
vivo. These data strongly support the further preclinical
characterization of this FDA-approved immunomodula-
tory anti-cancer drug as a potential treatment for TBI in
the clinic.
This study may be the first to demonstrate that Pom
possesses efficacious neuroprotective properties that,
based upon our data, is mediated via an anti-
inflammatory mechanism of action on brain glial cells.
This property is in accord with our prior evaluation of
3,6′-dithiothalidomide, a structurally related and like-
wise more potent TNF-α lowering analog of thalidomide
[66]. It has been suggested that the timing of anti-
inflammatory therapies with regard to the initial injury
may prove to be critical for the determination of benefi-
cial over harmful longer term drug effects [67, 68]; thus,
great care must be taken in designing any therapeutic
agent treatment regimen. Studies in mice generated to
either lack TNF-α or its receptors suggest that elevated
TNF-α is damaging during the acute period following a
TBI but is involved in regenerative processes during the
later chronic post-injury phase [54, 69, 70]. In particular,
signaling via TNF-α receptor 1 (p55) has been implicated
in the immediate deleterious actions of injury-induced
acute TNF-α release, with knockout mice demonstrating a
reduced contusion volume and improved neurobehavioral
performance for up to 4 weeks following CCI TBI versus
wild-type mice [71]. In contrast, TNF-α receptor 2 (p75)
knockout mice demonstrated exacerbated post-injury
[68], suggesting an involvement of this receptor in the
later tissue repair.
The implication from our study is that the window
of therapeutic intervention for Pom is up to and in-
cluding 5 h after TBI and appears to close by 7 h.
Notably, this is in accord with that observed in a re-
cent study in which cellular apoptosis was blocked by
the use of pharmacological p53 inactivators to define
the cellular population that are amenable to rescue
[28]. It may be the case that if a larger Pom dose-
effect study had been undertaken, a different drug
dose-dependent therapeutic window relationship—pos-
sibly longer—may have been identified. This possibil-
ity requires further characterization to be proven or
disproven. Our previous studies inhibiting TNF-α syn-
thesis in a milder form of TBI, involving a weight
drop concussive injury in mice, demonstrated a thera-
peutic window of 12 h that closed within 18 h [20];
this suggests a relationship between TBI severity and
the point at which the secondary phase of brain in-
jury can be halted or reversed.
Strengths of the controlled cortical impact TBI model
system in rodent are the reproducibility of the injury
and the readily measurable changes in tissue morph-
ology subsequent to injury, a measure amenable to the
detection of beneficial therapeutic manipulation. Add-
itional features of the model that align with TBI seen in
the clinical setting include disruption of the blood-brain
barrier and the recruitment of peripheral blood mono-
nuclear cells that, taken together, create a useful model
for the study of penetrating injuries of the dura mater
and candidate drug treatments. The observed alterations
in rodent motor function and cortical cellular and histo-
logical measures were not associated with any TBI- or
Pom-induced lowering of animal body temperature, a
confound in studies of beneficial influences on neuronal
survival following a TBI [71, 72]. A potential caveat of
the present study is that experimental animals were eu-
thanized 24 h after the induction of the brain injury,
which is in line with prior TBI and stroke studies by
others and ourselves [28, 73, 74]. Nonetheless, signifi-
cant attenuations of TBI-induced pathology and func-
tional measures were observed during this relatively
short time frame—suggestive of more long-term drug
benefits after TBI. However, further studies will need to
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be performed to confirm this speculation. As important,
longer term studies would allow evaluation of potential
adverse drug actions (for example, peripheral neuropathy
and/or immunosuppression—which were not evaluated
after our single dose short-term study).
Pom has been investigated in various rodent models of
human disease including peripheral blood cell cancer, brain
and colorectal cancer, and models of dermal fibrosis [75–
80]. The doses of Pom utilized in such studies ranged from
0.3 up to 50 mg/kg body weight administered on daily or on
an alternate daily schedule for 2 to 6 weeks. Drug delivered
was by the oral or intraperitoneal routes. To our knowledge,
our study is the first to evaluate Pom in a model of TBI.
Interestingly, the dose of Pom (0.5 mg/kg) used in our study
is similar to that used in other experimental investigations
[75–80]. An additional insight from the present study is that
a single administration of Pom was able to provide signifi-
cant benefits to a range of outcome measures after TBI. If
this feature were to translate to the treatment of human
TBI, it may suggest that there could be a reduced occur-
rence of the documented, undesirable effects associated with
prolonged treatment with Pom [25]. The dose and adminis-
tration regiment of Pom utilized for the clinical treatment of
multiple myeloma is 4 mg once daily taken on days 1–21 of
repeated 28-day cycles [25], but doses as high as 10 mg have
been administered. The equivalent human dose of Pom that
matches to that used in our rat TBI study (0.5 mg/kg), when
normalized to body surface area across species in accord
with FDA guidelines, is approximately 5 mg for a 60- to 65-
kg human [81]. This dose is similar to that currently used in
clinical practice today.
Until quite lately, the molecular target of thalidomide and
its analogs was not known but was recently identified as the
protein cereblon [82]. Cereblon has been described as a
direct protein target of Pom, and a physical drug-protein
interaction appears responsible for the observed immuno-
modulatory properties of this class of medicines [83], albeit
recent studies have demonstrated that Pom can inhibit cyto-
kines in cereblon deficient mice [84]—suggesting potential
involvement of additional pathways in some cells. Cereblon
mRNA appears to be widely distributed in the adult rodent
brain with almost all neurons expressing it, whereas levels
observed in astrocytes and associated cells are reported to
be the modest to negligible [85]. Cereblon may play several
roles in the physiology of brain tissues: impairing the func-
tion of certain neuronal cell ion channels, a calcium ion
channel (BKCa) [86], and a chloride channel (CIC-2) [87, 88].
Cereblon also interacts with proteins that bind with dam-
aged DNA, targeting the complexes for ubiquitination and
proteasomal degradation [87]. It has been reported to bind
with the α-subunit of AMP-activated protein kinase
(AMPK) that interferes with the normal function of
AMPK, a critical sensor of cellular energetics. Al-
though little is known in relation to cereblon
following brain injury, its depletion in mouse embryonic
fibroblasts results in resistance to a broad number of cyto-
toxic insults, including oxidative stress, and knocking out
cereblon in mice results in a reduced infarct volume in
the middle cerebral occlusion model of stroke [89].
Hence, in addition to the effects of Pom on TNF-α regu-
lation [66], Pom may provide pleiotrophic effects by bind-
ing to and sequestering cereblon. Thus, Pom may inhibit
potential cereblon-mediated detrimental physiological ac-
tions on stressed neurons leading to neuroprotection after
TBI. Clearly, more studies will be required to identify any
specific effects of Pom and cereblon on TBI-compromised
neuronal tissues and in neuroinflammation. Taken to-
gether, the present study identifies an interesting candi-
date agent for development as a treatment of TBI in the
clinic—a possible new medicine for a highly prevalent
medical condition that presently has none.
Conclusions
Post-injury treatment with a single clinically translatable
dose of Pom within 5 h significantly mitigated functional
impairments in a well-characterized animal model of
controlled cortical impact TBI. Pom reduced the injury
lesion volume, improved neuronal survival, and amelio-
rated ensuing neuroinflammation. These findings advo-
cate further appraisal and optimization of Pom as a new
treatment strategy for clinical TBI.
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